跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 44 条关于
“Velsera”
全部
44
临床试验
11
药物
7
机构
4
资讯
22
2年前
Velsera Technology Drives Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight Oncology Comprehensive IVD
2年前
FDA Approves Illumina's TruSight Oncology Comprehensive IVD with Velsera Technology
去年
Tessera Therapeutics Reports Breakthrough Gene Editing Results for Multiple Genetic Diseases
去年
Metsera's MET-097 Demonstrates Significant Weight Loss in Phase 1 Trial, Supporting Monthly Dosing Potential
去年
Metsera Aims for $289 Million IPO to Advance GLP-1RA Obesity Treatment
去年
Metsera Secures $215 Million to Advance Weight Loss Drug Pipeline
去年
Metsera's MET-097i Shows Promise in Phase I/II Obesity Trial, Advancing to Phase II
去年
Metsera Secures $215 Million to Advance Obesity and Metabolic Disease Therapies
10个月前
Novo Nordisk Pursues Metsera Acquisition with Amended Proposal to Strengthen Obesity Pipeline
10个月前
Pfizer Raises Metsera Acquisition Offer to $86.25 Per Share Amid Novo Nordisk Competition
第 1 页,共 3 页
上一页
下一页